You are here » Home » Companies » Company Overview » Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd.

BSE: 524703 Sector: Health care
NSE: N.A. ISIN Code: INE751D01014
BSE 16:01 | 06 Jul 66.90 1.05
(1.59%)
OPEN

65.15

HIGH

67.40

LOW

65.10

NSE 05:30 | 01 Jan Sandu Pharmaceuticals Ltd
OPEN 65.15
PREVIOUS CLOSE 65.85
VOLUME 3429
52-Week high 86.00
52-Week low 43.35
P/E 37.17
Mkt Cap.(Rs cr) 59
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 65.15
CLOSE 65.85
VOLUME 3429
52-Week high 86.00
52-Week low 43.35
P/E 37.17
Mkt Cap.(Rs cr) 59
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Sandu Pharmaceuticals Ltd. (SANDUPHARMA) - Chairman Speech

Company chairman speech

The challenges of covid-19 are far from over the emergence of thesecond wave earlier this year and talks of another wave likely in the future means that wemight have to cope with the related challenges in the months to come. Our decision toadopt a "fearless and agile" organisation helped Sandu Pharma "successfullyride the storm" in FY21 We have been able to minimise the impact of the second waveon the company's supply chains as well as demand for our products. That said I amhappy to state that we as an organization are better prepared to handle these challengesas compared with last year. We are applying the learnings from last year includingstreamlining supply chains to ensure minimal disruption in availability of its products.I am confident that Sandu Pharma is well positioned to meet the challenges ahead andgenerate sustainable long-term growth.

The emergence of the second and more devastating wave of the pandemicin mid April going up to June of 2021 tested the character of the organization all overagain. As we stayed true to our Ayurvedic roots while working tirelessly towards servingall our stakeholders the health and safety of our employees remained paramount.

We rolled out a series of initiatives across our operations to preventthe spread of infection the company launched many more new products like Immunity Kit andPower Herbs range.

Distribution enhancement initiatives and increased flexibility into ourplanning and go-to-market strategies.

The Economy made a good recovery during the second half with mostcountries trying to coming back to good growth driven by consumer connect initiativescost efficiencies and innovation. With the consumers becoming more health conscious thecompany we expects to see good momentum. Today the penetration of healthcare products islow compared to the developed markets so there is a opportunity to grow. Due to increaseddemand we have geared up our manufacturing capacities in products like Sandu Chawanprashand Makarprash to meet the surge in demand for other products too the Company is ready tomeet the enhanced demand.

I am happy to inform you that our company has shown a 20 % jump inSales.

"Continued investments behind key products and increasingdistribution footprint coupled with a structured and balanced approach to costmanagement helped Company to overcome the challenging suituations of covid in the yeargone by.

We are seeing revival in the overall Classical Ayurvedic productscategory.

E-commerce vertical is showing great promise and sales are up 100%year-on-year.

Presently the Company's Products are being sold through leadingEcommerce market places and Company is actively in touch with other leading EcommerceMarket places for its products to be sold through them. We are also gearing up to sellthrough Company's own ecommerce market places.

.